GALT
Galectin Therapeutics Inc. NASDAQ Listed Sep 4, 2002$2.11
After hrs
$2.10
+0.00%
Mkt Cap $138.9M
52w Low $1.21
15.2% of range
52w High $7.13
50d MA $2.67
200d MA $3.94
P/E (TTM)
-4.7x
EV/EBITDA
-16.3x
P/B
—
Debt/Equity
-1.1x
ROE
24.1%
P/FCF
-11.1x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$2.67
200d MA
$3.94
Avg Volume
317.5K
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
4960 Peachtree Industrial Boulevard · Norcross, GA 30071 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.10 | -0.08 | +20.0% | 2.79 | -0.4% | -3.9% | -4.3% | -8.2% | -21.5% | -20.4% | — |
| Nov 14, 2025 | AMC | -0.11 | -0.13 | -18.2% | 5.51 | +1.8% | +8.9% | +12.3% | +4.2% | +4.2% | -2.9% | — |
| Aug 14, 2025 | AMC | -0.16 | -0.12 | +25.0% | 3.76 | +0.8% | -5.1% | +3.7% | -0.3% | +3.7% | +3.2% | — |
| May 15, 2025 | AMC | -0.20 | -0.15 | +25.0% | 1.32 | -1.5% | -3.0% | +0.8% | -2.3% | -3.0% | -3.0% | — |
| Mar 31, 2025 | AMC | -0.16 | -0.19 | -18.8% | 1.22 | +0.0% | +3.3% | +8.2% | +4.9% | +8.2% | +9.0% | — |
| Nov 14, 2024 | AMC | -0.20 | -0.18 | +10.0% | 2.75 | +1.8% | +0.7% | -2.2% | +0.4% | +2.5% | -1.1% | — |
| Aug 13, 2024 | AMC | -0.16 | -0.20 | -25.0% | 2.25 | -1.3% | -7.6% | -2.7% | +3.1% | +4.4% | +2.2% | — |
| May 15, 2024 | AMC | -0.16 | -0.19 | -18.8% | 3.06 | +0.3% | +2.6% | +5.6% | +3.3% | +5.6% | +1.6% | — |
| Mar 29, 2024 | AMC | -0.16 | -0.16 | +0.0% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.16 | -0.24 | -50.0% | 1.95 | +0.0% | -7.2% | -4.1% | -3.1% | +0.5% | -4.1% | — |
| Aug 14, 2023 | AMC | -0.21 | -0.15 | +28.6% | 1.49 | -1.3% | +7.4% | +5.4% | +16.1% | +8.1% | +8.7% | — |
| May 15, 2023 | AMC | -0.21 | -0.19 | +9.5% | 1.64 | +1.2% | -1.2% | +1.8% | +0.3% | +6.7% | +11.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.20 | $6.57 | +6.0% | +4.4% | -0.6% | -29.4% | -35.0% | -35.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.67 | $3.69 | +0.5% | +2.5% | -2.7% | +6.3% | +2.2% | +6.3% |
| Apr 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.26 | $1.23 | -2.4% | +4.8% | +1.6% | +4.8% | +5.6% | +0.8% |
| Dec 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.87 | $0.90 | +3.6% | +32.2% | +26.4% | +48.3% | +34.5% | +33.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.80 | +1.8% | +0.7% | -2.2% | +0.4% | +2.5% | -1.1% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.18 | -0.5% | +5.9% | +7.3% | +5.0% | +6.4% | +5.5% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.74 | +0.0% | +5.3% | +2.1% | +12.3% | +6.1% | +4.5% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.39 | +0.0% | +2.1% | +5.0% | +19.2% | +25.5% | +56.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.47 | -1.3% | +7.4% | +5.4% | +16.1% | +8.1% | +8.7% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.62 | $1.63 | +0.6% | +3.1% | +1.5% | +8.0% | +12.3% | +11.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.25 | +1.4% | +8.1% | -2.3% | -3.6% | -7.2% | -5.4% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.39 | +10.3% | +7.1% | +1.6% | +4.8% | +1.6% | +4.8% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.27 | +1.8% | -1.8% | +24.7% | +21.1% | +32.3% | +55.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.71 | +3.8% | +10.0% | +17.6% | +16.9% | +11.9% | +18.0% |
| Apr 3 | B. Riley Securities | Maintains | Buy → Buy | — | $1.66 | $1.65 | -0.6% | +3.6% | +10.2% | +3.6% | +5.4% | +10.5% |
| Apr 3 | B. Riley FBR | Maintains | Buy → Buy | — | $1.66 | $1.65 | -0.6% | +3.6% | +10.2% | +3.6% | +5.4% | +10.5% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.66 | $1.70 | +2.4% | +4.8% | -9.0% | -0.6% | +6.0% | +3.6% |
| Feb 13 | B. Riley FBR | Maintains | Buy → Buy | — | $4.46 | $4.78 | +7.2% | +3.4% | +11.4% | +14.8% | +16.6% | +33.9% |
| Oct 19 | Roth Capital | Maintains | Buy → Buy | — | $2.51 | $2.60 | +3.6% | -0.8% | +6.0% | +1.2% | +4.8% | +3.6% |
| Oct 6 | Seaport Global | Maintains | Buy → Buy | — | $2.43 | $2.54 | +4.5% | +0.4% | +7.4% | +14.4% | +13.6% | +12.3% |
| Mar 30 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.98 | $2.16 | +9.1% | +2.5% | +16.2% | +10.1% | +8.1% | +8.6% |
| Mar 30 | H.C. Wainwright | Upgrade | Neutral → Buy | — | $1.98 | $2.16 | +9.1% | +2.5% | +16.2% | +10.1% | +8.1% | +8.6% |
| Oct 3 | FBR Capital | Downgrade | Outperform → Market Perform | — | $1.13 | $1.12 | -0.9% | +1.8% | -1.8% | -6.2% | -10.6% | -16.1% |
| Sep 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.40 | $1.33 | -5.0% | -12.9% | -19.3% | -17.9% | -20.7% | -24.3% |
| Sep 29 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $1.40 | $1.33 | -5.0% | -12.9% | -19.3% | -17.9% | -20.7% | -24.3% |
| Sep 28 | Roth Capital | Downgrade | Buy → Sell | — | $2.47 | $1.20 | -51.4% | -43.3% | -50.6% | -54.3% | -53.4% | -55.1% |
| Sep 21 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.28 | $2.40 | +5.3% | +5.3% | +2.2% | +1.3% | -0.4% | -6.6% |
| Aug 1 | Aegis Capital | Downgrade | Buy → Hold | — | $6.14 | $5.98 | -2.6% | -7.3% | -13.2% | -8.8% | -9.4% | -10.9% |
| Apr 2 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $13.58 | $13.65 | +0.5% | +3.4% | -2.4% | -10.1% | -12.1% | -11.3% |
| Feb 12 | Aegis Capital | Maintains | Buy → Buy | — | $15.46 | $15.70 | +1.6% | +4.6% | +3.4% | -4.1% | +0.0% | -1.3% |
| Oct 7 | Ascendiant Capital | Maintains | Buy → Buy | — | $11.00 | $11.13 | +1.2% | +9.6% | +1.0% | -7.1% | +1.7% | +1.3% |
| Jul 25 | Aegis Capital | Maintains | Buy → Buy | — | $2.48 | $2.82 | +13.7% | +13.7% | +3.6% | +8.8% | +2.4% | -5.6% |
| Jul 6 | Dawson James | Maintains | Buy → Buy | — | $1.89 | $1.75 | -7.4% | -1.6% | +1.6% | -2.1% | -2.6% | -2.6% |
No insider trades available.
8-K
Unknown — 8-K Filing
Galectin Therapeutics is furnishing supplementary risk disclosure without formal SEC filing, suggesting potential material developments that warrant investor review of the complete 10-K filing for full context.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Loss of a highly accomplished neurosurgery expert with 40+ years of NIH funding and 416 publications weakens GALT's scientific credibility and innovation pipeline in its core brain tumor treatment business.
Mar 17
Data updated apr 25, 2026 10:39am
· Source: massive.com